Cargando…
Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids
IMPORTANCE: Buprenorphine is an effective and cost-effective medication to treat opioid use disorder (OUD), but is not readily available to many people with OUD in the US. The current cost-effectiveness literature does not consider interventions that concurrently increase buprenorphine initiation, d...
Autores principales: | Claypool, Anneke L., DiGennaro, Catherine, Russell, W. Alton, Yildirim, Melike F., Zhang, Alan F., Reid, Zuri, Stringfellow, Erin J., Bearnot, Benjamin, Schackman, Bruce R., Humphreys, Keith, Jalali, Mohammad S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199347/ https://www.ncbi.nlm.nih.gov/pubmed/37204803 http://dx.doi.org/10.1001/jamahealthforum.2023.1080 |
Ejemplares similares
-
Enumerating contributions of fentanyls and other factors to the unprecedented 2020 rise in opioid overdose deaths: model-based analysis
por: Stringfellow, Erin J, et al.
Publicado: (2023) -
Reducing opioid use disorder and overdose deaths in the United States: A dynamic modeling analysis
por: Stringfellow, Erin J., et al.
Publicado: (2022) -
Opioid overdose decedent characteristics during COVID-19
por: Garcia, Gian-Gabriel P., et al.
Publicado: (2022) -
Factors Associated With Abrupt Discontinuation of Long-Term High-Dose Opioid Treatment
por: Vivas-Valencia, Carolina, et al.
Publicado: (2023) -
Modeling the evolution of the US opioid crisis for national policy development
por: Lim, Tse Yang, et al.
Publicado: (2022)